Medical/Pharmaceuticals
Clario and XingImaging expand partnership to deliver PET imaging clinical trials in China
BEIJING and PRINCETON, N.J., Jan. 11, 2022 /PRNewswire/ -- Clario, a technology company that delivers the leading endpoint technology solutions for clinical trials, and XingImaging, a radiopharmaceutical production and positron emission tomography (PET) acquisition company, have expanded their pa...
2022-01-11 21:00
3931
SOPHiA GENETICS Reports Strong Traction in the Launch Phase of its DEEP-Lung-IV Multimodal Clinical Study
BOSTON and LAUSANNE, Switzerland, Jan. 11, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (NASDAQ: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today strong traction in the launch phase of their DEEP-Lung-IV clinical study (NCT0...
2022-01-11 20:27
2413
China's 2021 U.S. Patent Grants Surged, Even as Total Patent Awards Trended Downward, According to Analysis by IFI CLAIMS
2021 Rankings Shed Light on Corporate R&D Priorities: Telemedicine, Supply Chain Efficiencies, E-Cigs and Artificial Intelligence Among Hottest Areas of Activity NEW HAVEN, Conn., Jan. 11, 2022 /PRNewswire/ -- Enhancements in telemedicine, more hardy grains to feed the world in a time of climate...
2022-01-11 18:00
2025
Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets
SHANGHAI and NEW YORK, Jan. 11, 2022 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading innovation-driven international healthcare group inChina and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)...
2022-01-11 16:30
4542
Latest Study Shows Encouraging Results of CanSinoBIO's Inhaled COVID-19 Vaccine as Heterologous Booster
TIANJIN, China, Jan. 11, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced thatPreprints with The Lancet, a collaboration between the research sharing platform SSRN and The Lancet, published a clinical study on the safety and immunogenicity of ...
2022-01-11 15:15
3296
SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections
COPENHAGEN, Denmark, Jan. 11, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is pleased to announce that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) Application, for our first development candidate, enabli...
2022-01-11 14:29
1849
MGI Aims to Boost its Market Share through Participation at Expo 2020 Dubai's Guangdong Week
DUBAI, UAE, Jan. 11, 2022 /PRNewswire/ -- Global life science innovator MGI Tech Co. Ltd. (MGI) is aiming to boost its market share in theMiddle East and Asia through participation at Guangdong Week, a dedicated event taking place at the world exhibition's China Pavilion fromJanuary 11-13. The ...
2022-01-11 14:00
2724
Pfizer Drives Cultural Change in Sustainable and Accessible Data with MicroStrategy
SINGAPORE, Jan. 11, 2022 /PRNewswire/ -- MicroStrategy
2022-01-11 09:30
3283
Keep Your Home Safe and Build a Protected Community Against Omicron with Circle HealthPod
* Circle HealthPod detects >99.9% of known COVID-19 strains, including the Omicron variant, in approximately 20 minutes * With technology developed at the University of Oxford, the Circle HealthPod is a CE-IVD marked rapid detection system with 98.4% molecular accuracy * Frequent testing wit...
2022-01-11 09:00
3228
Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication
HANGZHOU, China and SHAOXING, China, Jan. 11, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC42 for chronic hepatitis B (CHB) indication. The Phase II clinical trial (ClinicalTrials.gov Identifier: NCT051...
2022-01-11 08:30
4334
Dr. Ivan Puah Highlights The Significant Impact Of Covid That Changes Our Priority In Life
SINGAPORE, Jan. 11, 2022 /PRNewswire/ -- The current pandemic has raised more awareness of the importance of health and better care of oneself. Dr.Ivan Puah, Medical Director at Amaris B. Clinic shares how people's lifestyles and priorities have changed since Covid-19 started. 01. Losing we...
2022-01-11 06:44
2644
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
SEATTLE, SAN FRANCISCO, SAN JOSE, Calif., NANJING, China, SUZHOU, China and SHANGHAI, Jan. 11, 2022 /PRNewswire/ -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmace...
2022-01-11 05:30
5131
The new symptoms of the COVID period that CDAHK doctors have uncovered
HONG KONG, Jan. 10, 2022 /PRNewswire/ -- As the COVID-19 Omicron variety continues to spread, chiropractors see a spike in neck pathology from work-from-home, remote learning during pandemic. For 30 years before the COVID-19 pandemic, the majority of chiropractic patients were suffering from bac...
2022-01-10 23:52
2674
New Resource from NCCN Shares Evidence-Based Approaches to Recognize and Manage Graft-Versus-Host Disease after Stem Cell Transplantation
PLYMOUTH MEETING, Pa., Jan. 10, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN®) today announced the publication of new NCCN Guidelines for Patients®: Graft-Versus-Host Disease (GVHD). GVHD is a complication that occurs after a donor stem cell or bone marrow (a.k.a. hematopo...
2022-01-10 21:37
2280
Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy® in Combination with KEYTRUDA® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer
SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- Everest Medicines
2022-01-10 21:35
5277
Clinical study on Bactiguard's endotracheal tube now published - shows significant reduction of ventilator-associated pneumonia
STOCKHOLM, Jan. 10, 2022 /PRNewswire/ -- The VITAL study, by Professor Pierre Damas and his team, is now published in the well renowned journal Annals of Intensive Care. The study shows a 53% reduction of ventilator-associated pneumonia with Bactiguard's endotracheal tube. It was presented for th...
2022-01-10 20:57
2356
Clarivate Identifies Seven Potential Blockbuster Drugs in Annual Drugs to Watch Report
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma Report also examines key therapeutic development areas to watch including mRNA, CRISPR, AI-driven drug discovery and more LONDON, Jan. 10, 2022 /...
2022-01-10 16:00
3354
Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors
HANGZHOU, China and SHAOXING, China, Jan. 10, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today the filing of the U.S. Investigational New Drug (IND) application for in-house developed oral PD-L1 small molecule inhibitor, ASC61, for the treatment of advanced solid tumors. AS...
2022-01-10 08:30
4442
Healthcare providers can expect to receive US$725 reimbursement from CMS when using NGS-based Sentosa(R) SQ HIV-1 Genotyping Assay
FAIRFIELD, N.J., Jan. 7, 2022 /PRNewswire/ -- Vela Diagnostics announced that itsSentosa® SQ HIV-1 Genotyping Assay is covered for reimbursement from The Centers for Medicare and Medicaid (CMS) startingJanuary 2022. Based on the 2022 Clinical Diagnostic Laboratory Fee Schedule by CMS, healthcare...
2022-01-07 22:00
2999
Elekta to appoint Tobias Hägglöv as Chief Financial Officer
STOCKHOLM, Jan. 7, 2022 /PRNewswire/ -- Elekta (STO: EKTA-B) announced today that it will appoint Tobias Hägglöv as Chief Financial Officer effective February 1, 2022, taking over from Johan Adebäck. Tobias Hägglöv has previously held the role of CFO at Recipharm as well as senior management posit...
2022-01-07 14:49
2857
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 295 media titles]
2026-09-18 16:29CityUHK and University of Cambridge establish Centre for Advanced and Smart Manufacturing to shape Hong Kong's Industry 5.0 future
[Picked up by 286 media titles]
2026-09-22 18:37
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
01F Group Announces Investment in DANA, Indonesia's Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia's Fintech Opportunity
[Picked up by 273 media titles]
2026-09-21 08:00Tetra Pak and Soy Excellence Center Asia Host Regional Soy Food and Beverage Programme in Thailand
[Picked up by 268 media titles]
2026-09-18 11:51
Most Read
COSRX Brings Its 5 Peptide Lip Collection to Ulta Beauty Stores Offline
2026-09-18 22:00
10257
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
2026-09-17 13:09
9451
Ohmyhome Limited Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
2026-09-17 20:00
7574
American Savings Bank Jumps More Than 6% in Trading Debut: NYSE Content Update
2026-09-17 21:21
7226
